These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 10203053)
21. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002 [TBL] [Abstract][Full Text] [Related]
22. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694 [TBL] [Abstract][Full Text] [Related]
23. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Pavone-Cossut MR; Macchia I; Farcomeni S; Tenner-Racz K; Racz P; Ensoli B; Titti F J Med Primatol; 2007 Aug; 36(4-5):180-94. PubMed ID: 17669207 [TBL] [Abstract][Full Text] [Related]
24. Control of Heterologous Simian Immunodeficiency Virus SIV Singh S; Ramírez-Salazar EG; Doueiri R; Valentin A; Rosati M; Hu X; Keele BF; Shen X; Tomaras GD; Ferrari G; LaBranche C; Montefiori DC; Das J; Alter G; Trinh HV; Hamlin C; Rao M; Dayton F; Bear J; Chowdhury B; Alicea C; Lifson JD; Broderick KE; Sardesai NY; Sivananthan SJ; Fox CB; Reed SG; Venzon DJ; Hirsch VM; Pavlakis GN; Felber BK J Virol; 2018 Aug; 92(15):. PubMed ID: 29793957 [TBL] [Abstract][Full Text] [Related]
25. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Kaur A; Sanford HB; Garry D; Lang S; Klumpp SA; Watanabe D; Bronson RT; Lifson JD; Rosati M; Pavlakis GN; Felber BK; Knipe DM; Desrosiers RC Virology; 2007 Jan; 357(2):199-214. PubMed ID: 16962628 [TBL] [Abstract][Full Text] [Related]
26. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905 [TBL] [Abstract][Full Text] [Related]
27. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236 [TBL] [Abstract][Full Text] [Related]
28. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus. Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490 [TBL] [Abstract][Full Text] [Related]
29. A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge. Patterson LJ; Robey F; Muck A; Van Remoortere K; Aldrich K; Richardson E; Alvord WG; Markham PD; Cranage M; Robert-Guroff M AIDS Res Hum Retroviruses; 2001 Jun; 17(9):837-49. PubMed ID: 11429125 [TBL] [Abstract][Full Text] [Related]
30. Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine. Liu Z; Singh DK; Sheffer D; Smith MS; Dhillon S; Chebloune Y; Hegde R; Buch S; Narayan O Virology; 2006 Aug; 351(2):444-54. PubMed ID: 16650448 [TBL] [Abstract][Full Text] [Related]
31. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys. Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581 [TBL] [Abstract][Full Text] [Related]
32. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160. Hu SL; Stallard V; Abrams K; Barber GN; Kuller L; Langlois AJ; Morton WR; Benveniste RE J Med Primatol; 1993; 22(2-3):92-9. PubMed ID: 8411113 [TBL] [Abstract][Full Text] [Related]
33. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. Egan MA; Charini WA; Kuroda MJ; Schmitz JE; Racz P; Tenner-Racz K; Manson K; Wyand M; Lifton MA; Nickerson CE; Fu T; Shiver JW; Letvin NL J Virol; 2000 Aug; 74(16):7485-95. PubMed ID: 10906202 [TBL] [Abstract][Full Text] [Related]
34. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187 [TBL] [Abstract][Full Text] [Related]
35. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. Polacino P; Stallard V; Klaniecki JE; Montefiori DC; Langlois AJ; Richardson BA; Overbaugh J; Morton WR; Benveniste RE; Hu SL J Virol; 1999 Jan; 73(1):618-30. PubMed ID: 9847367 [TBL] [Abstract][Full Text] [Related]
36. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Hutnick NA; Myles DJ; Hirao L; Scott VL; Ferraro B; Khan AS; Lewis MG; Miller CJ; Bett AJ; Casimiro D; Sardesai NY; Kim JJ; Shiver J; Weiner DB Vaccine; 2012 May; 30(21):3202-8. PubMed ID: 22406458 [TBL] [Abstract][Full Text] [Related]
37. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249 [TBL] [Abstract][Full Text] [Related]
38. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. Patterson LJ; Malkevitch N; Venzon D; Pinczewski J; Gómez-Román VR; Wang L; Kalyanaraman VS; Markham PD; Robey FA; Robert-Guroff M J Virol; 2004 Mar; 78(5):2212-21. PubMed ID: 14963117 [TBL] [Abstract][Full Text] [Related]
39. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Putkonen P; Quesada-Rolander M; Leandersson AC; Schwartz S; Thorstensson R; Okuda K; Wahren B; Hinkula J Virology; 1998 Oct; 250(2):293-301. PubMed ID: 9792840 [TBL] [Abstract][Full Text] [Related]
40. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]